Futibatinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), CIPM (Spain) and NICE (England), among others, recommended or restricted futibatinib, while HAS (France) and PBAC (Australia) did not recommend it.
Every record falls within a 1.9-year window, 30 Aug 2023 to 2025 — a compressed review cycle.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 11 of 11 records date from 2023 or later.
3 distinct indication wordings are recorded for futibatinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 11 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CHUIKYO (Japan) was first to assess futibatinib, on 30 Aug 2023; PBAC (Australia) did not open a file until 2025 — a moderate spread of 1.9 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 11 dated records fall in 2024 alone.
PBAC (Australia) is the only agency to have returned to futibatinib, recording 3 separate entries.
9 of the 18 agencies in this archive hold a record for futibatinib.
The full ledger for futibatinib reads 3 recommended, 3 not recommended, 1 deferred and 1 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Bile duct cancer (cholangiocarcinoma) | Not recommended | source |
| SMC (Scotland) | 7 Apr 2025 | For treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that hav… | accepted | source |
| G-BA (Germany) | 22 Nov 2024 | Lytgobi — benefit assessment §35a | added benefit: not proven | source |
| NYE METODER (Norway) | 22 Sep 2024 | Monoterapi til behandling av voksne med lokalt avansert eller metastatisk kolangiokarsinom (gallegangskreft) med fibrobl… | decision recorded | source |
| NICE (England) | 11 Sep 2024 | NICE TA1005 | recommended (optimised) | source |
6 further decisions for futibatinib, across 5 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 11 decisions for futibatinib from 9 agencies, 2023 to 2025. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.